Ioannis Tsinopoulos

Dr. Ioannis Tsinopoulos

Laboratory of Experimental Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Michael TsatsosMichael Tsatsos
Michael Tsatsos
CDChryseis Delimitrou
Chryseis Delimitrou
ITIoannis Tsinopoulos
Ioannis Tsinopoulos
NZNikolaos Ziakas
Nikolaos Ziakas
Ocular surface squamous neoplasia (OSSN) includes a variety of ocular surface tumors ranging from mild epithelial dysplasia to invasive squamous cell carcinoma. OSSN is one of the most frequent non-pigmented malignancies of the ocular surface. Debate persists between surgical excision and medical management concerning the optimal regimen for OSSN treatment, with surgical excision continuing to be the recognized standard of care in contemporary medicine. Medical and conservative therapy techniques have advanced significantly in recent years, leading to widespread use in everyday ophthalmology practice. This study aims to look into the efficacy of current treatment options for conjunctival squamous cell carcinoma and to evaluate the available evidence for the most up-to-date approach for the management of the disease.

Verified
Journal Article
Open access
PDF file
Michael TsatsosMichael Tsatsos
Michael Tsatsos
KKKonstantina Koulotsiou
Konstantina Koulotsiou
IGIOANNIS GIACHOS
IOANNIS GIACHOS
ITIoannis Tsinopoulos
Ioannis Tsinopoulos
NZNikolaos Ziakas
Nikolaos Ziakas
Purpose: Pellucid Marginal Degeneration (PMD) is a rare ectatic corneal disorder characterized by inferior peripheral thinning and significant irregular astigmatism. Despite its clinical similarities to keratoconus, PMD presents unique diagnostic and therapeutic challenges. This review aims to provide a comprehensive update on the pathophysiology, clinical features, diagnostic approaches, and management strategies for PMD, emphasizing the latest advancements in treatment options. Methods: A systematic literature search was performed in MEDLINE (via PubMed), Google Scholar, and Scopus up to February 2025 using the terms: “pellucid marginal degeneration,” “PMD,” “ectatic corneal disorders,” “keratoplasty in PMD,” “corneal cross-linking in PMD,” “ICRS in PMD,” “toric IOL PMD” and their Boolean combinations (AND/OR). The search was restricted to English-language studies involving human subjects, including case reports, case series, retrospective studies, clinical trials, and systematic reviews. A total of 76 studies met the inclusion criteria addressing treatment outcomes in PMD. Results: PMD is characterized by a crescent-shaped band of inferior corneal thinning, leading to high irregular astigmatism and reduced visual acuity. Diagnosis relies on advanced imaging techniques such as Scheimpflug-based corneal tomography, which reveals the characteristic “crab-claw” pattern. Conservative management includes rigid gas-permeable (RGP) lenses and scleral lenses, which provide effective visual rehabilitation in mild to moderate cases. Surgical options, such as CXL, ICRS, and toric IOLs, are reserved for advanced cases, with varying degrees of success. Newer techniques such as CAIRS, employing donor tissue instead of synthetic rings, show promising outcomes in corneal remodeling with potentially improved biocompatibility. Penetrating keratoplasty (PK) and deep anterior lamellar keratoplasty (DALK) remain definitive treatments for severe PMD, though they are associated with significant risks, including graft rejection and postoperative astigmatism. Conclusions: PMD is a complex and progressive corneal disorder that requires a tailored approach to management. Early diagnosis and intervention are critical to optimizing visual outcomes. While conservative measures are effective in mild cases, surgical interventions offer promising results for advanced disease. Further research is needed to refine treatment protocols and improve long-term outcomes for patients with PMD.

Verified
Journal Article
Open access
PDF file
Eirini Kanella PanagiotopoulouEirini Kanella Panagiotopoulou
Eirini Kanella Panagiotopoulou
TPThomas Polychroniadis
Thomas Polychroniadis
Minas BakirtzisMinas Bakirtzis
Minas Bakirtzis
ITIoannis Tsinopoulos
Ioannis Tsinopoulos
NZNikolaos Ziakas
Nikolaos Ziakas
Georgios LabirisGeorgios Labiris
Georgios Labiris
Background/Objectives: Swept-Source Optical Coherence Tomography (SS-OCT) is a novel optical biometry technology with limited published data on its reliability compared to the gold standard, partial coherence interferometry (PCI). This study aims to assess the agreement between an SS-OCT biometer (Argos) and a PCI device (IOLMaster 500) in terms of biometry values, intraocular lens (IOL) power calculation and mean prediction error (ME). Methods: In this prospective comparative study, axial length (AL), anterior chamber depth (ACD), flat (K1), steep (K2) and mean (Km) keratometry values, astigmatism power, J0, and J45 vector components, white-to-white distance (WTW), and IOL power calculations for nine IOL models using four formulas were compared in cataract patients. Refractive outcomes were assessed in eyes implanted with SN60WF and Panoptix IOLs, with ME calculated for each module and formula for both IOLs postoperatively. Results: This study included 133 eyes (mean age: 66.0 ± 10.95 years). Argos measured significantly higher ACD and steeper keratometry values than IOLMaster, albeit without significant differences in AL, astigmatism power, WTW, J0, and J45. Mean IOL power differences were within the clinically acceptable threshold (0.50 D), except for SN6ATx with Hoffer Q and Haigis, and Clareon with Haigis. For Panoptix and SN60WF, IOLMaster demonstrated a more hyperopic ME than Argos with SRK/T, Holladay 1, and Hoffer Q; however, this was without clinically significant differences. Conclusions: Argos and IOLMaster 500 presented differences in ACD, keratometry values, and IOL power calculation. However, both devices showed non-clinically significant differences in IOL power calculation and ME in the majority of formulas.